Aflibercept in Patients With Pigment Epithelial Detachments (PED)

Inclusion Criteria: * Patients with vascular PED due to AMD * Male or female patients with the age \> 50 years * Angiographic and via OCT ensured PED ≥ 200 µm in the eye for treatment * Written informed consent * Best corrected visual acuity (ETDRS-Visus): 24 - 73 letters within Exclusion Criteria: * Patients that do not fulfill the a. m. inclusion criteria * Patients which have been treated with steroids or with verteporfin via photodynamic therapy or focal lasercoagulation treatment until 3 months before, * Anti VEGF therapy until 1 month before screening * Patients with other retinal vascular diseases including diabetic rethinopathia or retinal vein occlusion * Other ocular operative procedurs 3 months before Screening * Anamnesis of non controlled glaucoma * Active or intraocular Inflammation or Inflammation of ocular adnexa * Subfoveal fibrosis within study eye * Larger surgical interventions 1 month before Screening * Anamnesis of serious cardiovascular diseases or stroke 6 months before srceening * Allergy of components of the study medication * Patients which might be not compliant * Patients participating at another clinical trial at the same time * Pregnancy, breastfeeding, women in child-bearing years without using a safe contraception method * Chronical alcohol- or drug abuse within the last year * lack of capacity and/or knowledge of German language * Neurologic disease i. e. multiple sclerosis